Optimal Duration of Hormonal Therapy for Unfavorable Intermediate-risk Prostate Cancer Patients: 6 Versus 12 Months. | ClinicalTrials HQ

Ask about research services

Swipe the table sideways for more columns.

Trial	Conditions	Status	Phase	Updated	More info	NCT ID
Optimal Duration of Hormonal Therapy for Unfavorable Intermediate-risk Prostate Cancer Patients: 6 Versus 12 Months.	Genital Diseases, Male Urogenital Diseases, Neoplasms by Histologic Type, Neoplasms by Site, Urogenital Diseases, Urogenital Neoplasms, adenocarcinoma, carcinoma, epithelial neoplasm, male reproductive organ cancer, male reproductive system disorder, neoplasm, prostate cancer, prostate disorder	Not yet recruiting	Phase 3	2025-03-04		NCT06855589

1 results · Page 1 of 1

Swipe the table sideways for more columns.

Organizations	Linked trials
Charles LeMoyne Hospital	3

5 results · Page 1 of 1

Swipe the table sideways for more columns.

Research sites	City	Country	Linked trials
Centre Hospitalier Universitaire de Sherbrooke	Sherbrooke	Canada	2
Hôpital Charles LeMoyne	Longueuil	Canada	1
Hôpital de Gatineau	Gatineau	Canada	1
Hôpital Maisonneuve-Rosemont	Montreal	Canada	4
Jewish General Hospital	Montreal	Canada	130